Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 14/20 | 0.50 |
| ▸ | TNF | P01375 | 5/20 | 0.50 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.50 |
| ▸ | IL1B | P01584 | 3/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.43 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19585510 | 0.85 | CRBN (0.54) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL30376144 | 0.81 | CRBN (0.40) | CRBNDDB1 | |
| SCHEMBL25305333 | 0.81 | CRBN (0.54) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL30066511 | 0.76 | CRBN (0.54) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL27099085 | 0.75 | CRBN (0.58) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL30135733 | 0.75 | CRBN (0.58) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL30066448 | 0.75 | TNF (0.51) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL32666643 | 0.74 | CRBN (0.44) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL30058666 | 0.74 | STAT3 (0.55) | CRBNIKZF3TNFIKZF1IL1B | |
| SCHEMBL19585659 | 0.74 | CRBN (0.63) | CRBNIKZF3TNFIKZF1IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017197056-A1 | BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |